Loading resource…

INSERM CIC1418, Hôpital Européen Georges Pompidou, APHP, Université Paris Cité, University of Washington
Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain low due to factors like low treatment adherence and therapeutic inertia. New drug therapies, including small interfering RNA agents and aldosterone synthase inhibitors, are being developed to improve hypertension management. The document emphasizes the importance of balancing the benefits of these innovations with considerations of safety, cost, and equitable access to reduce the burden of cardiovascular and chronic kidney disease.
No account needed